health management
contain the unproven cis CoQ10. Kaneka CoQ10 is found • S.K. Baker and M.A. Tarnopolsky, “Targeting Cellular Energy
in food, drink, tablets, capsules, skin cream, toothpaste, Production in Neurological Disorders,” Expert Opin. Investig. Drugs
mouthwash and chewing gum. 12(10), 1655–1679 (2003).
• C.W. Shults, et al., “Effects of Coenzyme Q10 in Early Parkinson Dis-
Conclusion ease: Evidence of Slowing of the Functional Decline,” Arch. Neurol.
With the third phase of a trial into the effects of CoQ10 in 59(10), 1541–1550 (2002).
Parkinson’s patients now under way and a further study ex- • S. Horowitz, “Coenzyme Q10: One Antioxidant, Many Promising
amining whether the nutrient improves mitochondrial function Implications,” Altern. Comp. Therapies 9(3), 111–116 (2003).
and depressed mood in bipolar patients, it seems unlikely that • U. Hoppe, et al., “Coenzyme Q10: A Cutaneous Antioxidant and
demand for this nutrient will diminish. One of the world’s fore- Energizer,” Biofactors 9(2–4), 371–378 (1999).
most authorities on CoQ10, Dr Peter Langsjoen, believes it is • L. Rusciani, et al., “Low Plasma Coenzyme Q10 Levels as an Inde-
as fundamentally important as vitamin C in maintaining health pendent Prognostic Factor for Melanoma Progression,”
and longevity: “As CoQ10 is essential to the optimal function J. Am. Acad. Dermatol. 54(2), 234–241 (2006).
of all cell types, it is not surprising to find a seemingly diverse • J.L. Quiles, et al., “Coenzyme Q Differentially Modulates Phospho-
number of disease states that respond favourably to CoQ10 lipid Hydroperoxide Glutathione Peroxidase Gene Expression and
supplementation.” Free Radicals Production in Malignant and Non-Malignant Prostate
Cells,” Biofactors 18(1–4), 265–270 (2003).
However, claims that CoQ10 is the new ‘wonder • J.M. Hodgson, et al., “Coenzyme Q10 Improves Blood Pressure
nutrient’ have left some scientists sceptical. and Glycaemic Control in a Controlled Trial in Subjects with Type 2
There is little doubt that abnormally low levels of Diabetes,” Eur. J. Clin. Nutr. 56(11), 1137–1142 (2002).
CoQ10 are a common factor in • K. Folkers and A. Wolaniuk, “Research on Coenzyme Q10 in Clinical
patients across a spectrum of Medicine and in Immunomodulation,” Drugs Exp. Clin Res. 11(8),
conditions, but many believe 539–545 (1985).
this could be a symptom • F.L. Rosenfeldt, et al., “Skeletal Myopathy Associated with Nucleo-
of their illness rather than a side Reverse Transcriptase Inhibitor Therapy: Potential Benefit of
cause. Nevertheless, scientists Coenzyme Q10 Therapy,” Int. J. STD AIDS 16(12), 827–829 (2005).
around the globe are optimistic • F. Gazdik, et al., “Decreased Levels of Coenzyme Q(10) in Patients
about the potential of CoQ10. with Bronchial Asthma,” Allergy 57(9), 811–814 (2002).
Dr Peter Langsjoen believes: “We • C.Q. Ye, et al., “A Modified Determination of Coenzyme Q10 in
have only scratched the surface of the bio- Human Blood and CoQ10 Blood Levels in Diverse Patients with Al-
medical and clinical applications of CoQ10.” lergies,” Biofactors 1(4), 303–306 (1988).
• J. Feher, et al., “Improvement of Visual Functions and Fundus
Although the fundamental benefits of CoQ10 are Alterations in Early Age-Related Macular Degeneration Treated with
undisputed, a question mark will remain over the a Combination of Acetyl-L-Carnitine, n-3 Fatty Acids and Coenzyme
extent of these benefits until the nutrient has under- Q10,” Opthalmologica 219(3), 154–166 (2005).
gone further trials. But, if tests continue to yield promis- • R. Kumar, G. Gautam and N.P. Gupta, “Drug Therapy for Idio-
ing results, demand for CoQ10 could skyrocket. pathic Male Infertility: Rationale Versus Evidence,” J. Urol. 176(4),
1307–1312 (2006).
Bibliography • S.A. Sheweita, A.M. Tilmisany and H. Al-Sawaf, “Mechanisms of
• P.H. Langsjoen, Introduction to Coenzyme Q10 (http://faculty. Male Infertility: Role of Antioxidants,” Curr. Drug Metab. 6(5),
washington.edu/~ely/coenzq10.html). 495–501 (2005).
• S. Sander, et al., “The Impact of Coenzyme Q10 on Systolic Func- • N.M. Ramadan and T.M. Buchanan, “New and Future Migraine
tion in Patients with Chronic Heart Failure,” J. Cardiac Fail. 12(6), Therapy,” Pharmacol. Therapeut 112(1), 199–212 (2006).
464–472 (2006). • P.S. Sandor, et al., “Efficacy of Coenzyme Q10 in Migraine Prophy-
• A. Kuettner, et al., “Influence of Coenzyme Q(10) and Cerivastatin laxis: A Randomized Controlled Trial,” Neurology 64(4),
on the Flow-Mediated Vasodilation of the Brachial Artery: Results of 713–715 (2005).
the ENDOACT Study,” Int. J. Cardiol. 98(3), 413–419 (2005). • H. Ikematsu, et al., “Safety Assessment of Coenzyme Q10 (Kaneka
• H. Langsjoen, et al., “Usefulness of Coenzyme Q10 in Clinical Cardi- Q10) in Healthy Subjects: A Double-Blind, Randomized, Placebo-
ology: A Long-Term Study,” Mol. Aspects Med. 15, 165–175 (1994). Controlled Trial,” Regul. Toxicol. Pharmacol. 44(3), 212–218 (2006).
• A.R. Gaby, “The role of Coenzyme Q10 in Clinical Medicine: Part
II. Cardiovascular Disease, Hypertension, Diabetes Mellitus and
Infertility,” Altern. Med. Rev. 1(3), 168–175 (2001).
• M.F. Beal, “Mitochondrial Dysfunction and Oxidative Damage in
Alzheimer’s and Parkinson’s Diseases and Coenzyme Q10 as a Po-
tential Treatment,” J. Bioenerg. Biomembr. 36(4), 381–386 (2004).
www.nutraceuticalmag.com may digital 2007 nutraceutical business & technology 27
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38